Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study

Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study

ABSTRACT Background Muscle‐invasive urothelial carcinoma (MIUC) is a highly aggressive cancer associated with poor prognosis. Despite advancements in treatment, the optimal therapeutic approach remains unclear. Immune checkpoint inhibitors, when added to chemotherapy, have shown promise in improving...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanjun Wang, Kaihua Zhong, Xingliang Tan, Qianghua Zhou, Lijuan Jiang, Kai Yao, Zhiming Wu
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Cancer Medicine
Subjects:
cisplatin
disease‐free survival
gemcitabine
muscle‐invasive urothelial carcinoma
overall survival
tislelizumab
Online Access:https://doi.org/10.1002/cam4.70661
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items